Galectin-3 interacts with naive and primed neutrophils, inducing innate immune responses.
The neutrophil is the first line of defense against infection. As a part of the innate immune response, neutrophils start to emigrate from blood to an affected site and their state is altered from passively circulating naïve to primed, and then to fully activated. The extent of neutrophil activation and their subsequent response varies depending on the stimuli and environment that neutrophils encounter. Because neutrophils can also induce deleterious effects on host tissues, tight regulation of recruitment and functions of neutrophils is required for efficient recovery. Galectin-3, a soluble beta-galactoside binding protein, of which expression is up-regulated during inflammation/infection, is suggested to be involved in various inflammatory responses. However, the precise roles of this lectin in innate immunity remain unknown, while it has been demonstrated that galectin-3 binds to naïve and primed neutrophils. Here we report that galectin-3 can induce L-selectin shedding and interleukin-8 production in naïve and primed neutrophils. These activities were shown to be dependent on the presence of the C-terminal lectin domain and the N-terminal nonlectin domain of galectin-3, which is involved in oligomerization of this lectin. We also found that, after galectin-3 binds to neutrophils, primed but not naïve neutrophils can cleave galectin-3, mainly through elastase, which results in the formation of truncated galectin-3 lacking the N-terminal domain. Together, these results suggest that galectin-3 activates naïve and primed neutrophils, and galectin-3-activated primed neutrophils have an ability to inactivate galectin-3.
Nieminen
Julie
J
Glycobiology Laboratory, Research Centre for Infectious Diseases, Laval University Medical Centre, Faculty of Medicine, Laval University, Québec, Canada.
St-Pierre
Christian
C
Sato
Sachiko
S
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D002352:Carrier Proteins / Q000037:antagonists & inhibitors / Q000276:immunology*; D006023:Glycoproteins / Q000037:antagonists & inhibitors / Q000276:immunology*; D006801:Humans; D007113:Immunity, Innate; D016209:Interleukin-8 / Q000096:biosynthesis / Q000276:immunology; D019041:L-Selectin / Q000276:immunology; D007785:Lactose / Q000494:pharmacology; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000276:immunology; D009504:Neutrophils / Q000201:enzymology / Q000276:immunology*; D010196:Pancreatic Elastase / Q000276:immunology; D013329:Structure-Activity Relationship; D016326:Extracellular Matrix Proteins
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D002352:Carrier Proteins; D006023:Glycoproteins; D016209:Interleukin-8; D019041:L-Selectin; D007785:Lactose; D009240:N-Formylmethionine Leucyl-Phenylalanine; D010196:Pancreatic Elastase; C081856:LGALS3BP protein, human; D016326:Extracellular Matrix Proteins